A retrospective chart review found that glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors were associated with benefits including weight loss and reduced use of insulin in patients with type 1 diabetes.
A recent study found that personalizing the timing of testing based on patients' albumin excretion rate and HbA1c level could reduce time with undetected kidney disease as well as testing frequency.
In a population-based Canadian study, the magnitude of the association between diabetes and risk of cardiovascular events decreased while that between cardiovascular disease (CVD) and such events remained stable.
A study showed that chronic kidney disease has declined among U.S. adults with diabetes. A meta-analysis found that sodium-glucose cotransporter-2 inhibitors prevented kidney decline similarly in those with and without diabetes. A survey identified knowledge gaps among prescribers on this topic.
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
Rationing was more common among younger patients, Black patients, and uninsured patients, according to an analysis of the 2021 National Health Interview Survey.